Immunostimulant Drugs: BCG, Cytokines, Vaccines, Immunoglobulins & Cancer Immunotherapy

Safety principle: A stronger immune response can help control infection or cancer, but it can also cause fever, inflammation, autoimmunity, capillary leak, thrombosis, infusion reactions or life-threatening cytokine toxicity. The indication, product, route and monitoring plan matter.

Learning objectives

After this lesson, the student should be able to describe innate and adaptive immune responses; classify immunostimulant approaches; explain active and passive immunisation; discuss microbial products, BCG, cytokines, colony-stimulating factors, immunoglobulins, historical small-molecule agents and modern cellular therapy; and prescribe or counsel safely within the limits of local guidelines and specialist care.

1. What are immunomodulators and immunostimulants?

Immunomodulators alter immune activity. They include drugs that suppress an excessive response (for example after transplantation or in autoimmune disease) and drugs that enhance, redirect or replace a protective response. Immunostimulants are the latter group: they increase one or more arms of immune defence, haematopoiesis or tumour-directed immunity.

That definition must be applied precisely. A vaccine stimulates antigen-specific immune memory; intravenous immunoglobulin supplies ready-made antibodies and is therefore a form of passive immunisation rather than a direct stimulant of the patient’s own lymphocytes; filgrastim stimulates neutrophil production; intravesical BCG creates a local anti-tumour immune reaction in the bladder; and CAR-T therapy gives a patient modified cells able to recognise cancer. These are not interchangeable therapies.

2. Immune-response foundations: why immunostimulants work

2.1 Innate immunity

The supplied lecture begins correctly with the innate response: it is the rapid first line of defence against an antigenic insult. It includes physical barriers such as skin and mucosal epithelium; biochemical defences including complement, lysozyme and interferons; and cellular defences including neutrophils, monocytes, macrophages, natural killer (NK) cells, mast cells and basophils.

Innate cells recognise conserved microbial patterns called pathogen-associated molecular patterns (PAMPs) through pattern-recognition receptors such as Toll-like receptors. This triggers cytokine production, phagocytosis, killing of microbes and activation of antigen-presenting cells. It is useful in early infection, but uncontrolled innate activation can produce sepsis-like inflammation, hypotension, organ injury and shock.

2.2 Adaptive immunity

Adaptive immunity is antigen-specific and generates memory. Humoral immunity is mediated by B lymphocytes and antibodies; it is especially important against extracellular microbes and toxins. Cell-mediated immunity is mediated mainly by T lymphocytes: CD4⁺ helper cells coordinate other immune cells, while CD8⁺ cytotoxic T cells kill infected or malignant cells. Regulatory T cells limit excessive responses. NK cells are innate lymphocytes but also contribute strongly to anti-viral and anti-tumour killing.

Vaccines aim to create long-lived B-cell, T-cell and antibody memory. Cytokines may increase the number or activity of selected immune cells. BCG and adjuvants activate innate pathways and antigen presentation. Adoptive cell transfer bypasses some natural limitations by supplying a large number of tumour-reactive lymphocytes.

3. Classification of immunostimulant strategies

4. Microbial products and BCG

4.1 Why microbial products stimulate immunity

Many bacterial products contain PAMPs. When recognised by antigen-presenting cells (APCs), they induce cytokines and co-stimulatory signals that strengthen T-cell and B-cell responses. This is the biological basis for using microbial components in vaccines and for using BCG as local cancer immunotherapy. It is also the reason these products can cause fever, inflammatory reactions and, rarely, severe systemic toxicity.

4.2 BCG: two completely different clinical uses

BCG is a live attenuated strain derived from Mycobacterium bovis. Students must separate its vaccine role from its intravesical bladder-cancer role.

The lecture states that BCG produces a granulomatous reaction and activates macrophages; this remains a useful teaching anchor. However, avoid the oversimplification that BCG only stimulates immunoglobulin production. Protection against tuberculosis and the anti-tumour effect both depend substantially on cell-mediated immune pathways. BCG vaccination is not a treatment for active tuberculosis and it is not automatically safe for every immunocompromised person.

4.3 Intravesical BCG: practical principles

Intravesical BCG is a proven immune-system modulator for selected intermediate- and high-risk non-muscle-invasive bladder cancer. It is administered into the bladder, not injected intravenously. It is commonly used after transurethral resection of a bladder tumour to lower recurrence and progression risk in appropriately selected patients. Treatment must be guided by urology/oncology protocols.

• Expected local/systemic effects: dysuria, frequency, urgency, haematuria, malaise, low-grade fever and flu-like symptoms.
• Important complications: severe cystitis, granulomatous inflammation, hypersensitivity reaction and rare disseminated BCG infection/sepsis.
• Red flags after treatment: persistent high fever, rigors, hypotension, respiratory symptoms, jaundice or severe systemic illness require urgent assessment.
• Do not confuse: BCG used for bladder cancer is live biological therapy; handling, timing, contraindications and infection-control precautions are specialist decisions.

5. Active immunisation: vaccines

Active vaccination exposes the immune system to an antigen safely enough to stimulate adaptive immunity and immunological memory. The antigen may be a whole attenuated organism, an inactivated organism, a toxoid, a purified protein/polysaccharide, a recombinant product, a viral vector or nucleic-acid instructions for an antigen. The goal is not an immediate antibody transfusion; it is durable, specific host immunity.

5.1 Steps in vaccine-induced immunity

1. Antigen is delivered and captured by APCs.
2. APCs present antigen to T cells and provide co-stimulation.
3. B cells receive help and differentiate into antibody-producing plasma cells and memory B cells.
4. T-cell memory and/or B-cell memory is established.
5. On later exposure, the immune response is faster and more effective.

5.2 Vaccine classes and clinical implications

The lecture notes that whole microbes can trigger inflammation that enhances memory. This concept is valid, but modern vaccine design deliberately balances immunogenicity with safety. More inflammation is not automatically better. Vaccine schedules, co-administration, contraindications and adverse-event reporting must follow current national immunisation guidance.

6. Vaccine adjuvants

Adjuvants are substances added to some vaccines to improve the immune response to the antigen. They may retain antigen at the injection site, improve uptake by APCs, activate innate receptors or enhance T-cell co-stimulation. Their purpose is to obtain reliable protection with an appropriate antigen dose and schedule.

Students should not generalise from older experimental adjuvants such as Freund’s complete adjuvant to licensed human vaccines. Freund’s adjuvant is a powerful research adjuvant and is not used routinely in human vaccination because of unacceptable reactogenicity. When counselling patients, distinguish normal short-lived local/systemic vaccine reactions from serious adverse events; never attribute unrelated disease to an adjuvant without evidence.

7. Passive immunisation and immune globulins

Passive immunisation provides preformed antibodies. It does not create the same immediate antigen-specific immune memory as active vaccination. It is especially useful when exposure has already occurred, when there is insufficient time for active immunisation to work, or when a patient cannot make adequate antibodies.

7.1 Types

• Normal human immunoglobulin: pooled donor immunoglobulin, used for antibody-replacement therapy and selected immunomodulatory indications.
• Specific/hyperimmune immunoglobulin: high titre of a desired antibody, for example hepatitis B, rabies, tetanus or varicella products where indicated.
• Routes: intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG) or intramuscular specific products, depending on formulation and indication.

7.2 Indications

Important situations include primary or secondary antibody-deficiency disorders; post-exposure prophylaxis for selected infections; and some immune-mediated diseases where IVIG has immunomodulatory rather than replacement intent. For rabies exposure, passive immunisation is only one part of appropriate post-exposure prophylaxis and must be combined with vaccine according to the current national protocol. Do not invent doses from memory; rabies, hepatitis B and tetanus decisions are time-critical and guideline-dependent.

7.3 Safety and monitoring

Common infusion effects include headache, fever, chills, nausea and infusion-site reactions. Serious risks include anaphylaxis/hypersensitivity, thrombosis, haemolysis, aseptic meningitis, acute kidney injury and volume overload in susceptible patients. Check indication, product, previous reactions, renal function, thrombosis risks, infusion rate and need for observation. A patient with an acute severe reaction needs immediate emergency management, not simply a slower infusion.

8. Cytokines: the body’s immune communication molecules

Cytokines are low-molecular-weight signalling proteins that coordinate immune and inflammatory responses. They can act autocrinely (on the cell that secreted them), paracrinely (on nearby cells) or endocrinely (at a distance through the circulation). Cytokines act in networks: they may be synergistic, antagonistic, pleiotropic and capable of inducing other cytokines. These properties explain both their therapeutic power and their toxicity.

8.1 Major cytokine-based therapeutic groups

8.2 Interferons

Interferons are antiviral and immunomodulatory cytokines. They bind cell-surface receptors and change gene expression, creating an antiviral state and modifying immune-cell activity. Their indications are highly product- and guideline-dependent. Interferon alfa has been used for particular viral infections and malignancies; interferon beta is used in selected multiple-sclerosis treatment; interferon gamma-1b has an important role in chronic granulomatous disease.

Typical adverse effects include flu-like symptoms, fatigue, fever, myalgia, headache, depression or neuropsychiatric effects, cytopenias, thyroid dysfunction and liver abnormalities. Baseline and follow-up monitoring depend on the exact interferon: review full blood count, liver function, thyroid function and mental health when relevant. Do not start or stop an interferon without specialist guidance.

8.3 Interleukin-2 / aldesleukin

IL-2 is a T-cell growth factor that can stimulate cytotoxic T cells and NK-cell activity. Aldesleukin is recombinant IL-2 used in selected oncology settings. It is a classic example of immunostimulation that cannot be treated casually: high-dose therapy may cause capillary leak, hypotension, renal dysfunction, arrhythmia, pulmonary oedema and severe systemic illness. It belongs in expert oncology centres with intensive monitoring.

8.4 Colony-stimulating factors: filgrastim and pegfilgrastim

G-CSF stimulates neutrophil precursor cells in bone marrow and increases circulating neutrophils. It is used to reduce the duration/risk of clinically significant neutropenia in appropriate chemotherapy settings, in severe chronic neutropenia, after selected marrow insults and for mobilisation of stem cells. It is not an antibiotic, does not replace fever assessment, and does not mean a neutropenic patient with fever can remain at home.

• Monitoring: full blood count and clinical response; timing relative to chemotherapy must follow the protocol.
• Common adverse effect: bone pain, often reflecting marrow stimulation.
• Serious adverse effects: splenic enlargement/rare rupture, acute respiratory symptoms, severe allergic reaction and marked leucocytosis; escalate concerning abdominal/shoulder pain, dyspnoea or systemic deterioration.
• Clinical rule: fever in a neutropenic cancer patient is an emergency requiring urgent guideline-based assessment and antimicrobials; growth factor is prevention/support, not a substitute for sepsis management.

9. Classical and small-molecule immunostimulants: modern status matters

9.1 Thalidomide and related immunomodulatory drugs

Thalidomide has complex immunomodulatory, anti-angiogenic and anti-neoplastic effects. The lecture links it to altered cytokine production, NK-cell activity, erythema nodosum leprosum and multiple myeloma. These links are important, but the wording must be updated: thalidomide is not a routine treatment for rheumatoid arthritis and should not be described simply as an “immune stimulant.” Its current use is tightly controlled in selected conditions, including multiple myeloma and severe erythema nodosum leprosum in settings where authorised.

Lenalidomide and pomalidomide are related immunomodulatory drugs used in specialist oncology/haematology. They also require pregnancy prevention and monitoring for cytopenias, thrombosis, infection and other product-specific toxicities.

9.2 Levamisole

Levamisole was originally developed as an anthelmintic and was historically described as restoring depressed B-cell, T-cell, monocyte and macrophage function. The lecture lists older uses such as adjuvant therapy with 5-fluorouracil for colon cancer and some immune-deficiency contexts. These are largely historical in many modern formularies; its availability and role have declined because of toxicity and better alternatives.

Important adverse effects include nausea, rash/flu-like symptoms and potentially serious agranulocytosis, vasculitis and neurologic toxicity. It also appears as an adulterant in illicit cocaine and can cause destructive vasculitic skin lesions with neutropenia. Therefore, do not promote levamisole as a simple immune booster; use only a current local indication under medical supervision.

9.3 Inosine pranobex / inosiplex (isoprinosine)

The lecture calls this a complex that augments cytokine production and lymphocyte responses, and lists herpesvirus-related conditions and subacute sclerosing panencephalitis. Inosine pranobex has variable regulatory approval and inconsistent evidence across countries. Where it is available, it may be used in selected viral conditions, but it is not a replacement for proven antiviral therapy, vaccination or HIV care. It can cause nausea, neurological symptoms and increased serum/urinary uric acid; assess gout, hyperuricaemia and renal-stone risk.

9.4 Thymic peptides, azimexon, imexon, methylinosine monophosphate and “immunocynin”

The source lists thymosin, azimexon, imexon, methylinosine monophosphate and immunocynin/immunocyanin. These names appear in older immunopharmacology teaching, experimental literature or limited regional use. Their listing in a lecture is not proof of modern routine clinical usefulness. For assessment purposes, know that such agents were investigated to enhance immune-cell function or anti-tumour responses. For patient care, verify the exact product, evidence, regulatory status and guideline recommendation; never prescribe from a historical list alone.

10. Adoptive cell transfer and cell-based vaccination

10.1 Adoptive cell transfer (ACT)

Adoptive cell transfer removes immune cells from a patient (or, in some settings, uses a donor-derived product), expands or engineers them outside the body, then infuses them to attack cancer. The supplied lecture describes tumour-infiltrating lymphocytes (TILs): these are lymphocytes found inside tumour tissue, some of which can recognise the tumour. Outside the tumour’s suppressive microenvironment, selected cells can be expanded and returned in large numbers.

Modern ACT includes TIL therapy and chimeric antigen receptor T-cell (CAR-T) therapy. CAR-T cells are T cells engineered to express a receptor that recognises a tumour antigen. These are not ordinary “drugs” that can be prescribed from a clinic shelf: they involve patient selection, specialised manufacturing, lymphodepleting treatment, hospital-level monitoring and management of severe immune toxicities.

10.2 Major ACT toxicities

• Cytokine-release syndrome (CRS): fever, hypotension, hypoxia and organ dysfunction from systemic immune activation.
• Immune-effector-cell-associated neurotoxicity syndrome (ICANS): confusion, aphasia, tremor, seizures or reduced consciousness.
• Prolonged cytopenias and infection risk.
• Tumour-lysis syndrome in selected high-burden malignancies.

These emergencies require rapid recognition and specialist protocols. The correct student response to a patient who becomes febrile, confused or hypotensive after cellular immunotherapy is urgent escalation, not reassurance that “immunostimulation is working.”

10.3 Dendritic-cell and cancer-treatment vaccines

Dendritic cells are powerful APCs. They can be loaded or “pulsed” with tumour antigens in vitro and returned to the patient to promote recognition of tumour cells. The lecture calls this cell-based vaccination. This remains an important concept, although most dendritic-cell vaccine approaches are specialised or investigational rather than routine. Sipuleucel-T is an example of an approved therapeutic cancer vaccine in a specific advanced prostate-cancer setting in some jurisdictions. Preventive vaccines against infection-related cancers, such as HPV vaccination, are different from therapeutic cancer vaccines.

11. Clinical uses: match the drug to the problem

12. Pre-treatment assessment and monitoring framework

1. Confirm the indication. Is the aim prevention, replacement, neutrophil recovery, tumour treatment or post-exposure prophylaxis?
2. Identify immune status. Check immunosuppression, active infection, malignancy, pregnancy potential, prior reactions and current medicines.
3. Check product-specific contraindications. Live products, immunoglobulins, cytokines and cellular therapies have different rules.
4. Obtain baseline tests as required. Examples include full blood count, renal/liver function, pregnancy test for teratogenic medicines and disease-specific investigations.
5. Plan observation. Infusion reactions, cytokine toxicity and live-biological complications require a clear escalation pathway.
6. Document counselling. Include expected effects, red flags, adherence and who to contact urgently.

13. Common misconceptions and corrections

14. Short clinical cases

15. High-yield examination and OSCE points

1. Define immunostimulant: an agent that enhances, directs or restores a useful immune/haematopoietic response.
2. Name innate components: barriers, complement, neutrophils, macrophages/monocytes, NK cells, mast cells and basophils.
3. Contrast humoral and cell-mediated immunity.
4. State BCG uses: vaccine role and intravesical therapy for selected bladder cancer.
5. Differentiate active from passive immunisation with one example each.
6. Define adjuvant and state why it is used.
7. Name cytokine therapies: interferons, IL-2 pathway and colony-stimulating factors.
8. State one important indication and one major adverse effect of filgrastim.
9. State the absolute safety warning for thalidomide: teratogenicity with strict pregnancy prevention.
10. Describe ACT: isolate/expand or engineer immune cells, then reinfuse to target cancer.
11. Name two serious CAR-T/ACT toxicities: cytokine-release syndrome and neurotoxicity.
12. Explain why immunoglobulin is passive immunisation, not a vaccine.

16. Summary

Immunostimulant therapy is a broad field rather than one class of “boosters.” Vaccines generate active, antigen-specific memory; immunoglobulins give immediate passive protection; BCG creates vaccine and tumour-directed immune responses in different settings; cytokines and colony-stimulating factors alter immune signalling or haematopoiesis; and modern cellular therapies equip immune cells to attack cancer. Benefit comes from matching a precisely defined product to a precisely defined clinical problem, while respecting substantial risks, monitoring requirements and local guideline differences.

---

Sources for further study

• Supplied lecture: Immunostimulants — Slideshare
• World Health Organization: Vaccines and immunization
• National Cancer Institute: Immune system modulators to treat cancer
• National Cancer Institute: Adoptive cell transfer
• MedlinePlus: Filgrastim injection
• MedlinePlus: Intravenous immune globulin
• National Cancer Institute: Bladder cancer treatment